• Propanc Biopharma received Nasdaq’s delisting notice on October 23, 2026; its securities face delisting November 2, 2026, unless it requests an appeal.
• Closing bids for its common stock failed Nasdaq’s $1 minimum requirement for 30 consecutive business days before October 21, 2026.
• A reverse stock split within the prior year makes it ineligible for the usual 180-calendar-day compliance period.
• Management intends to appeal by October 30, 2026; requesting an appeal would stay delisting pending a hearings panel decision.
• The company believes it cured the bid-price deficiency following the notice; delisting could reduce stock liquidity and constrain equity financing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-049298), on October 29, 2026, and is solely responsible for the information contained therein.